

Chim C Lang

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4564467/chim-c-lang-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217
papers

10,774
citations

54
h-index

99
g-index

238
ext. papers

13,171
ext. citations

7.9
avg, IF

6
L-index

#	Paper	IF	Citations
217	Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. <i>Lancet, The</i> , 2005 , 366, 1640-9	40	2008
216	Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. <i>Circulation</i> , 2003 , 107, 294-9	16.7	429
215	Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. <i>Circulation Research</i> , 2016 , 119, 652-65	15.7	326
214	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020 , 41, 1810-1817	9.5	277
213	Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1995 , 76, 1259-65	3	261
212	Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. <i>Lancet, The</i> , 2010 , 375, 2161-7	40	243
211	The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. <i>Lancet, The</i> , 2011 , 378, 676-83	40	236
210	Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 687-94	15.1	216
209	Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Circulation</i> , 2006 , 113, 986-94	16.7	194
208	Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 1382-9	12.7	162
207	High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. <i>European Heart Journal</i> , 2014 , 35, 2312-21	9.5	147
206	Attenuation of isoproterenol-mediated vasodilatation in blacks. <i>New England Journal of Medicine</i> , 1995 , 333, 155-60	59.2	142
205	Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. <i>Nature Communications</i> , 2020 , 11, 163	17.4	140
204	Normalization of acquired QT prolongation in humans by intravenous potassium. <i>Circulation</i> , 1997 , 96, 2149-54	16.7	135
203	Vasodilation in black Americans: attenuated nitric oxide-mediated responses. <i>Clinical Pharmacology and Therapeutics</i> , 1997 , 62, 436-43	6.1	131
202	AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease. <i>Clinical Science</i> , 2009 , 116, 607-20	6.5	121
201	Hemodynamic exercise testing. A valuable tool in the selection of cardiac transplantation candidates. <i>Circulation</i> , 1996 , 94, 3176-83	16.7	116

200	Increased vascular adrenergic vasoconstriction and decreased vasodilation in blacks. Additive mechanisms leading to enhanced vascular reactivity. <i>Hypertension</i> , 2000 , 36, 945-51	8.5	114
199	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017 , 19, 627-634	12.3	110
198	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1081-1090	15.1	108
197	Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 570-6	15.1	108
196	Intravenous sodium nitrite in acute ST-elevation myocardial infarction: a randomized controlled trial (NIAMI). <i>European Heart Journal</i> , 2014 , 35, 1255-62	9.5	107
195	Diagnostic value of B-type natriuretic peptide concentrations in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 1996 , 78, 284-7	3	107
194	Relationship between peripheral and coronary function using laser Doppler imaging and transthoracic echocardiography. <i>Clinical Science</i> , 2008 , 115, 295-300	6.5	105
193	High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 926-32	15.1	104
192	Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. <i>American Heart Journal</i> , 1994 , 127, 1635-6	4.9	103
191	A systems BIOlogy Study to Tailored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2016 , 18, 716-26	12.3	94
190	Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 820-8	15.1	89
189	Peak cardiac power output, measured noninvasively, is a powerful predictor of outcome in chronic heart failure. <i>Circulation: Heart Failure</i> , 2009 , 2, 33-8	7.6	89
188	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019 , 394, 1254-1263	40	83
187	Cardiovascular Effects of Switching From Tobacco Cigarettes to Electronic Cigarettes. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 3112-3120	15.1	83
186	The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019 , 21, 965-973	12.3	81
185	Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2284-93	15.1	76
184	Non-cardiac comorbidities in chronic heart failure. <i>Heart</i> , 2007 , 93, 665-71	5.1	76
183	Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. <i>Journal of the American College of Cardiology</i> , 2009 , 53, 747-53	15.1	75

182	Ease of noninvasive measurement of cardiac output coupled with peak VO ₂ determination at rest and during exercise in patients with heart failure. <i>American Journal of Cardiology</i> , 2007 , 99, 404-5	3	74
181	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018 , 271, 132-139	3.2	74
180	Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 117-22	15.1	73
179	Targeting the renin-angiotensin-aldosterone system in heart failure. <i>Nature Reviews Cardiology</i> , 2013 , 10, 125-34	14.8	72
178	Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 960-8	15.1	67
177	Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , 2010 , 106, 1006-10	3	66
176	Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial. <i>Circulation</i> , 2020 , 142, 1713-1724	16.7	62
175	Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study. <i>European Journal of Heart Failure</i> , 2016 , 18, 94-102	12.3	61
174	The effect of metformin on insulin resistance and exercise parameters in patients with heart failure. <i>European Journal of Heart Failure</i> , 2012 , 14, 1303-10	12.3	61
173	Repurposing Metformin for Cardiovascular Disease. <i>Circulation</i> , 2018 , 137, 422-424	16.7	60
172	A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 1021-6	1.9	60
171	Dietary sodium loading increases plasma brain natriuretic peptide levels in man. <i>Journal of Hypertension</i> , 1991 , 9, 779-82	1.9	57
170	Effect of sympathoinhibition on exercise performance in patients with heart failure. <i>Circulation</i> , 1997 , 96, 238-45	16.7	57
169	A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. <i>European Heart Journal</i> , 2019 , 40, 3409-3417	9.5	56
168	Prognostic significance and measurement of exercise-derived hemodynamic variables in patients with heart failure. <i>Journal of Cardiac Failure</i> , 2007 , 13, 672-9	3.3	56
167	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 1269-1277	12.3	56
166	A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. <i>European Heart Journal</i> , 2020 , 41, 3421-3432	9.5	55
165	Effects of vitamin D supplementation on markers of vascular function after myocardial infarction--a randomised controlled trial. <i>International Journal of Cardiology</i> , 2013 , 167, 745-9	3.2	54

164	The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent pancardiac Target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. <i>European Heart Journal</i> , 2007 , 28, 1678-82	9.5	54
163	Selective low-level leg muscle training alleviates dyspnea in patients with heart failure. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1602-8	15.1	54
162	The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 2084-91	15.1	52
161	Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 41-6	6.1	51
160	Pulmonary Arterial Hypertension: Pathophysiology and Treatment. <i>Diseases (Basel, Switzerland)</i> , 2018 , 6,	4.4	50
159	Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of Microvascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. <i>European Heart Journal</i> , 2017 , 38, 1222-1229	9.5	49
158	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. <i>Diabetes Care</i> , 2020 , 43, 1356-1359	14.6	48
157	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2017 , 19, 1284-1293	12.3	46
156	Sacubitril/valsartan: beyond natriuretic peptides. <i>Heart</i> , 2017 , 103, 1569-1577	5.1	45
155	Efficacy and cost of an exercise program for functionally impaired older patients with heart failure: a randomized controlled trial. <i>Circulation: Heart Failure</i> , 2012 , 5, 209-16	7.6	44
154	Elevated heart rate and cardiovascular outcomes in patients with coronary artery disease: clinical evidence and pathophysiological mechanisms. <i>Atherosclerosis</i> , 2010 , 212, 1-8	3.1	42
153	Skeletal muscle mass and exercise performance in stable ambulatory patients with heart failure. <i>Journal of Applied Physiology</i> , 1997 , 82, 257-61	3.7	42
152	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2018 , 20, 923-930	12.3	41
151	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. <i>Cardiovascular Diabetology</i> , 2016 , 15, 97	8.7	41
150	Cardiopulmonary exercise variables in diastolic versus systolic heart failure. <i>American Journal of Cardiology</i> , 2008 , 102, 203-6	3	40
149	The functional consequence of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers. <i>Cardiovascular Drug Reviews</i> , 2007 , 25, 280-8		40
148	Morbidity and mortality in diabetic patients following cardiac transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2003 , 22, 244-9	5.8	40
147	The effects and costs of home-based rehabilitation for heart failure with reduced ejection fraction: The REACH-HF multicentre randomized controlled trial. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 262-272	3.9	40

146	Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study. <i>European Journal of Heart Failure</i> , 2012 , 14, 162-7	12.3	39
145	Insulin resistance: a potential new target for therapy in patients with heart failure. <i>Cardiovascular Therapeutics</i> , 2008 , 26, 203-13	3.3	38
144	Abnormalities of the QT interval in primary disorders of autonomic failure. <i>American Heart Journal</i> , 1998 , 136, 664-71	4.9	38
143	Selenium and outcome in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 1415-1423	12.3	38
142	Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. <i>European Journal of Heart Failure</i> , 2019 , 21, 732-743	12.3	37
141	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). <i>International Journal of Epidemiology</i> , 2018 , 47, 380-381j	7.8	37
140	Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. <i>British Journal of Clinical Pharmacology</i> , 2004 , 58, 332-5	3.8	37
139	Measurement of coronary vasomotor function: getting to the heart of the matter in cardiovascular research. <i>Clinical Science</i> , 2004 , 107, 449-60	6.5	37
138	Both high and low HbA1c predict incident heart failure in type 2 diabetes mellitus. <i>Circulation: Heart Failure</i> , 2015 , 8, 236-42	7.6	35
137	Altered coronary vasomotor function in young patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1904-9		35
136	Symptom Onset in Aortic Stenosis: Relation to Sex Differences in Left Ventricular Remodeling. <i>JACC: Cardiovascular Imaging</i> , 2019 , 12, 96-105	8.4	35
135	Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. <i>British Journal of Clinical Pharmacology</i> , 1996 , 41, 69-72	3.8	34
134	Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2019 , 21, 877-886	12.3	34
133	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018 , 39, 3867-3875	9.5	33
132	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018 , 253, 84-90	3.2	32
131	Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial. <i>BMJ Open</i> , 2017 , 7, e018097	3	31
130	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. <i>European Heart Journal</i> , 2019 , 40, 3616-3625	9.5	31
129	Usefulness of non-invasive measurement of cardiac output during sub-maximal exercise to predict outcome in patients with chronic heart failure. <i>American Journal of Cardiology</i> , 2009 , 104, 1556-60	3	30

128	Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 95-110		30
127	Efficacy of noninvasive cardiac imaging tests in diagnosis and management of stable coronary artery disease. <i>Vascular Health and Risk Management</i> , 2017 , 13, 427-437	4.4	28
126	Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure. <i>Diseases (Basel, Switzerland)</i> , 2017 , 5,	4.4	27
125	Epicardial adipose tissue is related to arterial stiffness and inflammation in patients with cardiovascular disease and type 2 diabetes. <i>BMC Cardiovascular Disorders</i> , 2018 , 18, 31	2.3	26
124	A randomised controlled trial of a facilitated home-based rehabilitation intervention in patients with heart failure with preserved ejection fraction and their caregivers: the REACH-HFpEF Pilot Study. <i>BMJ Open</i> , 2018 , 8, e019649	3	26
123	Pacing-induced heart disease: understanding the pathophysiology and improving outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 877-86	2.5	25
122	Iron Therapy in Heart Failure: Ready for Primetime?. <i>Cardiac Failure Review</i> , 2018 , 4, 28-32	4.2	25
121	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2128-2136	15.1	24
120	Resting heart rate and outcomes in patients with cardiovascular disease: where do we currently stand?. <i>Cardiovascular Therapeutics</i> , 2013 , 31, 215-23	3.3	24
119	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019 , 21, 112-120	12.3	24
118	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 386-398	15.1	22
117	Management of Noncardiac Comorbidities in Chronic Heart Failure. <i>Cardiovascular Therapeutics</i> , 2015 , 33, 300-15	3.3	22
116	Therapeutic development in cardiac syndrome X: a need to target the underlying pathophysiology. <i>Cardiovascular Therapeutics</i> , 2009 , 27, 49-58	3.3	22
115	Coronary vasomotor function is abnormal in first-degree relatives of patients with type 2 diabetes. <i>Diabetes Care</i> , 2007 , 30, 150-3	14.6	22
114	Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of nonsympathetic factors in blood pressure maintenance in blacks. <i>Hypertension</i> , 1997 , 30, 157-62	8.5	22
113	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020 , 22, 1147-1155	12.3	22
112	The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: A decision model-based analysis. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 1252-1261	3.9	20
111	Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study. <i>International Journal of Cardiology</i> , 2013 , 167, 2695-9	3.2	20

110	Morbidity and mortality of UNOS status 1B cardiac transplant candidates at home. <i>Journal of Heart and Lung Transplantation</i> , 2003 , 22, 419-26	5.8	20
109	Identification of novel biomarkers in plasma for prediction of treatment response in patients with heart failure. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S26	4.0	19
108	Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 260-267	12.3	19
107	Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 229	2.3	18
106	Clinical Role of CA125 in Worsening Heart Failure: A BIOSTAT-CHF Study Subanalysis. <i>JACC: Heart Failure</i> , 2020 , 8, 386-397	7.9	17
105	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. <i>Clinical Research in Cardiology</i> , 2020 , 109, 331-338	6.1	17
104	Adverse prognosis associated with asymmetric myocardial thickening in aortic stenosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2018 , 19, 347-356	4.1	16
103	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 983-991	12.3	16
102	Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis. <i>Heart</i> , 2019 , 105, 1149-1159	5.1	15
101	Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond. <i>Vascular Health and Risk Management</i> , 2015 , 11, 283-95	4.4	15
100	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002471	5.2	14
99	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries. <i>European Journal of Heart Failure</i> , 2020 , 22, 1472-1482	12.3	14
98	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020 , 22, 70-80	12.3	14
97	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. <i>Circulation: Heart Failure</i> , 2019 , 12, e005544	7.6	13
96	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019 , 12, e002470	5.2	13
95	Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. <i>Cardiovascular Therapeutics</i> , 2015 , 33, 1-8	3.3	13
94	Effect of CYP3A inhibition on vesparginone metabolism in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 506-11	6.1	13
93	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2019 , 21, 218-226	12.3	13

92	Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2020 , 8, 234-242	7.9	12
91	The role of cardiac biochemical markers in aortic stenosis. <i>Biomarkers</i> , 2016 , 21, 316-27	2.6	12
90	Genetic variants predicting left ventricular hypertrophy in a diabetic population: a Go-DARTS study including meta-analysis. <i>Cardiovascular Diabetology</i> , 2013 , 12, 109	8.7	12
89	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1048-1059	6.1	12
88	COVID-19-Associated Cardiovascular Complications. <i>Diseases (Basel, Switzerland)</i> , 2021 , 9,	4.4	12
87	Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension. <i>Journal of Hypertension</i> , 2019 , 37, 2481-2489	1.9	12
86	Genetic Variation in Kruppel like Factor 15 Is Associated with Left Ventricular Hypertrophy in Patients with Type 2 Diabetes: Discovery and Replication Cohorts. <i>EBioMedicine</i> , 2017 , 18, 171-178	8.8	11
85	A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 821-833	12.3	11
84	Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis. <i>European Journal of Heart Failure</i> , 2019 , 21, 1291-1294	12.3	11
83	Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones. <i>Heart Failure Clinics</i> , 2012 , 8, 539-50	3.3	11
82	Angiotensin converting enzyme inhibition and sympathetic activity in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 668-74	6.1	11
81	Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration: Potential Relevance to COVID-19 Risk. <i>Circulation</i> , 2020 , 142, 1117-1119	16.7	11
80	Chronotherapy in hypertension: the devil is in the details. <i>European Heart Journal</i> , 2020 , 41, 1606-1607	9.5	11
79	Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. <i>Pharmacogenomics Journal</i> , 2020 , 20, 770-783	3.5	9
78	Iron deficiency in heart failure: Efficacy and safety of intravenous iron therapy. <i>Cardiovascular Therapeutics</i> , 2017 , 35, e12301	3.3	9
77	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. <i>European Journal of Heart Failure</i> , 2020 , 22, 2102-2111	12.3	9
76	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018 , 104, 606-613	5.1	9
75	Aortic valvular heart disease: Is there a place for angiotensin-converting-enzyme inhibitors?. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 107-14	2.5	8

74	Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: a population cohort study. <i>European Journal of Heart Failure</i> , 2015 , 17, 90-7	12.3	8
73	Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021 , 23, 1750-1758	12.3	8
72	Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine. <i>Cardiovascular Therapeutics</i> , 2015 , 33, 104-8	3.3	7
71	Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. <i>ESC Heart Failure</i> , 2020 , 7, 1168-1177	3.7	7
70	Right ventricular pacing impairs endothelial function in man. <i>Europace</i> , 2011 , 13, 853-8	3.9	7
69	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019 , 108, 797-805	6.1	7
68	Population-level incidence and monitoring of adverse drug reactions with long-term amiodarone therapy. <i>Cardiovascular Therapeutics</i> , 2017 , 35, e12258	3.3	6
67	The future of pharmacogenetics in the treatment of heart failure. <i>Pharmacogenomics</i> , 2015 , 16, 1817-272.6		6
66	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. <i>European Journal of Internal Medicine</i> , 2020 , 71, 62-69	3.9	6
65	Effects of the coronary artery disease associated LPA and 9p21 loci on risk of aortic valve stenosis. <i>International Journal of Cardiology</i> , 2019 , 276, 212-217	3.2	6
64	Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021 , 23, 436-444	12.3	6
63	Differential Association of Genetic Risk of Coronary Artery Disease With Development of Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Circulation</i> , 2019 , 139, 986-988	16.7	5
62	An increased B-type natriuretic peptide in the absence of a cardiac abnormality identifies those whose left ventricular mass will increase over time. <i>JACC: Heart Failure</i> , 2015 , 3, 87-93	7.9	5
61	Biomarkers of Aortopathy in Marfan Syndrome. <i>Cardiology in Review</i> , 2020 , 28, 92-97	3.2	5
60	Myocardial ischaemia is associated with an elevated brain natriuretic peptide level even in the presence of left ventricular systolic dysfunction. <i>European Journal of Heart Failure</i> , 2014 , 16, 56-67	12.3	5
59	Potential mechanisms for the effects of far-infrared on the cardiovascular system - a review. <i>Vasa - European Journal of Vascular Medicine</i> , 2019 , 48, 303-312	1.9	5
58	Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. <i>Circulation</i> , 2020 , 142, 546-555	16.7	5
57	Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study). <i>European Journal of Heart Failure</i> , 2021 , 23, 1182-1190	12.3	5

56	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021 , 8, 3168-3179	3.7	5
55	Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2021 , 23, 43-57	12.3	5
54	The APEX trial: Effects of allopurinol on exercise capacity, coronary and peripheral endothelial function, and natriuretic peptides in patients with cardiac syndrome X. <i>Cardiovascular Therapeutics</i> , 2018 , 36, e12311	3.3	5
53	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018 , 15, 35	5	5
52	Underutilization of IV nitrates in the treatment of acute heart failure. <i>Cardiovascular Therapeutics</i> , 2015 , 33, 247-52	3.3	4
51	Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. <i>Heart Rhythm</i> , 2012 , 9, 505-10	6.7	4
50	Metformin: still the sweet spot for CV protection in diabetes?. <i>Current Opinion in Pharmacology</i> , 2020 , 54, 202-208	5.1	4
49	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. <i>European Journal of Heart Failure</i> , 2021 , 23, 947-953	12.3	4
48	Process evaluation of a randomised pilot trial of home-based rehabilitation compared to usual care in patients with heart failure with preserved ejection fraction and their caregiver\$. <i>Pilot and Feasibility Studies</i> , 2021 , 7, 11	1.9	4
47	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , 2021 , 117, 2228-2236	9.9	3
46	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 953-963	3.7	3
45	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020 , 109, 967-977	6.1	3
44	Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure. <i>Current Heart Failure Reports</i> , 2014 , 11, 31-9	2.8	3
43	Global array-based transcriptomics from minimal input RNA utilising an optimal RNA isolation process combined with SPIA cDNA probes. <i>PLoS ONE</i> , 2011 , 6, e17625	3.7	3
42	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 519-527	12.3	3
41	The value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 , 12, 555-567	10.3	3
40	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , 2021 , 23, 567-577	12.3	3
39	Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 746382	5.4	3

38	Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis. <i>Circulation: Cardiovascular Imaging</i> , 2020 , 13, e011763	3.9	2
37	Genetic Risk of Diverticular Disease Predicts Early Stoppage of Nicorandil. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 1171-1175	6.1	2
36	Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 140-8	3	2
35	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , 2021 , 24, 192	12.3	2
34	Impaired High-Density Lipoprotein Function in Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2021 , 10, e019123	6	2
33	Cardiac rehabilitation in heart failure with reduced ejection fraction: A "should take it and not leave it" intervention. <i>American Heart Journal</i> , 2017 , 192, e1-e2	4.9	1
32	Pathophysiological pathways related to high plasma GDF-15 concentrations in patients with heart failure.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	1
31	Optimal carbohydrate antigen 125 cutpoint for identifying low-risk patients after admission for acute heart failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 ,	0.7	1
30	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , 2021 , 44, 780-788	3.3	1
29	Type 2 Diabetes, Metabolic Traits, and Risk of Heart Failure: A Mendelian Randomization Study. <i>Diabetes Care</i> , 2021 , 44, 1699-1705	14.6	1
28	Effect of metformin on epicardial adipose tissue in patients with coronary artery disease without diabetes: A cardiac MRI substudy of the MET-remodel trial. <i>Obesity Medicine</i> , 2021 , 24, 100349	2.6	1
27	Determinants of Exercise Capacity and Myocardial Perfusion Reserve in Asymptomatic Patients With Aortic Stenosis. <i>JACC: Cardiovascular Imaging</i> , 2020 , 13, 178-180	8.4	1
26	A heart failure phenotype stratified model for predicting 1-year mortality in patients admitted with acute heart failure: results from an individual participant data meta-analysis of four prospective European cohorts. <i>BMC Medicine</i> , 2021 , 19, 21	11.4	1
25	Nicorandil-induced colovesical fistula in a patient with diverticular disease. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, 1737-1741	0.7	1
24	A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT. <i>Programme Grants for Applied Research</i> , 2021 , 9, 1-100	1.5	1
23	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021 ,	3.7	1
22	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).. <i>Trials</i> , 2022 , 23, 307	2.8	1
21	Contrast Induced Nephropathy: Efficacy of matched hydration and forced diuresis for prevention in patients with impaired renal function undergoing coronary procedures-CINEMA trial.. <i>IJC Heart and Vasculature</i> , 2022 , 39, 100959	2.4	0

20	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022 , 17, 228-239	6.9	o
19	Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK. <i>PLoS Medicine</i> , 2020 , 17, e1003372	11.6	o
18	Guideline Adherence of Eblocker Initiating Dose and its Consequence in Hospitalized Patients With Heart Failure With Reduced Ejection Fraction.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 770239	5.6	o
17	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	o
16	65 Incidence and Monitoring of Adverse Drug Reactions in Long-Term Amiodarone Therapy: a Retrospective Analysis in Tayside, Scotland. <i>Heart</i> , 2015 , 101, A35.2-A36	5.1	
15	Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial". <i>Circulation</i> , 2020 , 141, e55-e56	16.7	
14	Changing Times at Cardiovascular Therapeutics. <i>Cardiovascular Drug Reviews</i> , 2008 , 26, 1-1		
13	The Role of the Heart Failure Specialist 2009 , 175-195		
12	Management of Non-cardiac Co-morbidities in Chronic Heart Failure 2015 , 231-248		
11	Reply. <i>Journal of Hypertension</i> , 2020 , 38, 177-178	1.9	
10	Effect of hypoglycaemia on measures of myocardial blood flow and myocardial injury in adults with and without type 1 diabetes: A prospective, randomised, open-label, blinded endpoint, cross-over study. <i>Endocrinology, Diabetes and Metabolism</i> , 2021 , 4, e00258	2.7	
9	Obituary. <i>Cardiovascular Therapeutics</i> , 2016 , 34, 3	3.3	
8	What is the added value of the waist-to-hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply. <i>European Journal of Heart Failure</i> , 2019 , 21, 132-133	12.3	
7	Medical Management of Rheumatic Heart Disease 2021 , 107-132		
6	Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)". <i>Circulation</i> , 2021 , 144, e38-e39	16.7	
5	Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK 2020 , 17, e1003372		
4	Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK 2020 , 17, e1003372		
3	Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK 2020 , 17, e1003372		

2 Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK **2020**, 17, e1003372

1 Genetic and pharmacological relationship between P-glycoprotein and increased cardiovascular risk associated with clarithromycin prescription: An epidemiological and genomic population-based cohort study in Scotland, UK **2020**, 17, e1003372